32 results about "Sequence motif" patented technology

In various aspects and embodiments, the invention provides a nucleic acid molecule comprising a nucleotide sequence encoding a 7β-hydroxysteroid dehydrogenase (7β-HSDH) mutant that catalyzes at least the stereospecific enzymatic reduction of a 7-ketosteroid to the corresponding 7-hydroxysteroid, wherein the mutant has, compared to the wildtype 7β-HSDH of SEQ ID NO:2, a decreased substrate inhibition and / or an altered cofactor usage, and the mutant has, in comparison with the wildtype 7β-HSDH of SEQ ID NO:2, 1 to 15 amino acid additions, substitutions, deletions and / or inversions in the sequence motif VMVGRRE corresponding to positions 36 to 42 of SEQ ID NO:2.

Screening assays are used to identify mutant homogentisate solanesyl transferase (HST) enzymes which are at least partially resistant to HST-inhibiting herbicides. Nucleic acids encoding the mutant HST enzyme proteins are made available and useful in modifying plants and plant parts so that they can be made herbicide resistant. Crop plants which express the mutant HST enzymes can be grown in the field and herbicides used to controlling unwanted other vegetation. The homogentisate solanesyltransferase (HST) enzyme or an active fragment thereof comprises the amino acid sequence motif: F[V / M]TX[F / Y] (SEQ ID NO: 1), wherein X is any amino acid; and wherein one or more of the amino acid residues of the motif are mutated.

To provide a fusion polypeptide.SOLUTION: A fusion polypeptide comprising at least one extended recombinant (XTEN) polypeptide fused to the N-terminus or C-terminus of a biologically active polypeptide, wherein the XTEN polypeptide is 150-3,000 amino acids in length, has a plurality of non-overlapping sequence motifs that are each 9-14 amino acids in length, and wherein at least 90% of amino acid residues of the XTEN polypeptide are glycine, alanine, serine, threonine, glutamic acid, or proline, and wherein the XTEN polypeptide comprises a barcode fragment, wherein the barcode fragment is 4-20 amino acids in length, occurs only once within the fusion polypeptide, and is located within a region that is 5%-50% of the length of the XTEN polypeptide as measured from an end of the XTEN polypeptide distal to the biologically active polypeptide.SELECTED DRAWING: Figure 3

The present invention is in the field of genetic editing tools and methods of genetic endineering. It relates to the engineering of rare-cutting endonucleases designed to contract highly repetitive motives in chromosomes, which are at the origin of certain genetic diseases, in particular the so-called "triplet repeat diseases", such as the Huntington disease. The invention encompasses the method for contracting the repetitive motives, the rare-cutting endonucleases for use to contract repetitive motives in a gene subjected to repeat disorder, the polynucleotides and vectors encoding thereof as well as the resulting pharmaceutical compositions.

The present invention relates to methods for engineering the variable region of antibodies or antigen binding fragments thereof, in particular to reduce the effect of anti-drug antibodies. In one aspect, there is provided a monoclonal antibody or antigen-binding fragment thereof, wherein an amino acid sequence of the antibody or fragment thereof is engineered to reduce immunogenicity of the antibody or fragment thereof when the antibody or fragment thereof is administered to a subject, wherein the amino acid sequence is engineered to comprise one or more N-X-S and / or N-X-T sequence motifs in a variable region of the monoclonal antibody or fragment thereof, and wherein X is any amino acid other than proline.

The present invention relates to a nutritionally optimized synthetic or recombinant collagen peptide comprising at least one amino acid sequence motif (glycine-X-Y)n, and the collagen peptide according to the invention for use in a method for therapeutic treatment of the human or animal body and products containing the collagen peptide according to the invention.

This document discloses polypeptides comprising an extended recombinant polypeptide (XTEN) containing multiple overlapping sequence motifs and one or more barcode fragments, which are releasable upon protease digestion and detectable from all other protease-releasable fragments. Some embodiments of these polypeptides also comprise a bioactive polypeptide, wherein advantageous embodiments include a protease-cleavable releasable segment capable of cleaving the link between the XTEN polypeptide and the bioactive polypeptide. Methods for preparing and using the polypeptides are also disclosed.

Described herein are olfactory receptor proteins having a modified C-terminal domain comprising a specific amino acid sequence motif, as well as related nucleic acid molecules, expression vectors, recombinant host cells, libraries, and methods and uses.

The invention relates to the field of gene editing, in particular to engineered cytosine deaminase as well as application and a method of the engineered cytosine deaminase in preparation of a DNA (deoxyribonucleic acid) or RNA (ribonucleic acid) site-specific base editing system, and the engineered cytosine deaminase is a substance obtained by mutation of any one or more of the following sites on a protein with an amino acid sequence as shown in SEQ ID NO.1: H11, H16, K30, T31, H56, Y132 and C171. The engineered cytosine deaminase can be used in a DNA or RNA base editing system, gene editing is more accurate and efficient, the off-target rate is low, and a CBE-ProACD base editing system can efficiently edit cytosine C in a GC motif of a target sequence.

The disclosure features chimeric antigen receptor (CAR) ligands, methods for making the same, and immunomodulatory compositions comprising the CAR ligands. The disclosure also features compositions and methods of using the immunomodulatory compositions, for example, to stimulate activation of CAR expressing cells.

The present invention relates to a synthetic DNA construct comprising (A) a nucleic acid encoding transfer RNA and (B) a 5' leader sequence, wherein the 5' leader sequence contains a sequence motif for controlling the expression level of the transfer RNA.

Described herein are olfactory receptor proteins having modified C-terminal domains containing specific amino acid sequence motifs, as well as related nucleic acid molecules, expression vectors, recombinant host cells, libraries, and methods and uses.

The present invention relates to methods for engineering the variable region of antibodies or antigen binding fragments thereof that bind TNF alpha to reduce the effect of anti-drug antibodies. In one aspect, there is provided a monoclonal antibody or antigen-binding fragment thereof, wherein an amino acid sequence of the antibody or fragment thereof is engineered to reduce immunogenicity of the antibody or fragment thereof when the antibody or fragment thereof is administered to a subject, wherein the amino acid sequence is engineered to comprise one or more N-X-S and / or N-X-T sequence motifs in a variable region of the monoclonal antibody or fragment thereof, and wherein X is any amino acid other than proline.

Disclosed herein are polypeptides comprising an extended recombinant polypeptide (XTEN) comprised of a plurality of overlapping sequence motifs and one or more barcode fragments releasable upon protease digestion and detectable from ail other proteolytic-ally releasable fragments. Certain embodiments of these polypeptides further comprise a biologically active polypeptide, wherein advantageous embodiments thereof comprise a releasable segment capable of proteolytic cleavage that cleaves the linkage between the XTEN polypeptide and the biologically active polypeptide. Methods of making and methods of using said polypeptides are also disclosed.

A grade of a specific microbial disease in a biological sample of a subject is determined. In one example, masked microbial reference genomes are used to determine the amount of free DNA molecules corresponding to a particular microbial species associated with a particular microbial disease. The masking may remove an area shared with another. In another example technique, end motifs are used for free DNA fragments from a subject and from a particular microbial species. A correlation between a subject and an amount of a set of terminal sequence motifs of a particular microbial species may be determined. The two groups of quantities of positive subjects are substantially more correlated than negative subjects.

The invention discloses a glycosylation point prediction method and device, a medium and equipment. The method comprises the following steps: firstly traversing a to-be-predicted protein sequence, finding out to-be-evaluated point locations conforming to an asparagine-X-serine or threonine sequence motif, then labeling the corresponding asparagine point locations and the serine or threonine point locations, inputting the labeled asparagine point locations and the labeled serine or threonine point locations into a protein language model to obtain a corresponding embedding matrix, and finally, predicting the protein sequence according to the embedding matrix. The method comprises the following steps: performing difference processing on two embedding matrixes and an embedding matrix output by a target protein original sequence, calculating L2 norms according to point locations to obtain two vectors, calculating a normalized cross mean value according to vector element values on the corresponding point locations to obtain an evaluation value, and comparing the evaluation value with a threshold value to judge whether the N glycosylation site is an N glycosylation site or not. Therefore, the N glycosylation site on the to-be-predicted protein sequence is obtained. Compared with the prior art, various test indexes are excellent, especially accuracy and precision are high, and the method adopts the pre-training model and does not need additional machine training.

The invention provides a circular RNA (Ribonucleic Acid) expression framework as well as application and a method thereof, the expression framework comprises an upstream expression framework and a downstream expression framework, the upstream expression framework comprises a sequence Motif 1 and a complementary sequence thereof, or Motif 2 and a complementary sequence thereof; the downstream expression framework comprises a sequence Motif 3 and a complementary sequence thereof; the Motif 1 is HKDNNWHDHNHNDHNHNHNDHWNWWHDHAB, and the Motif 1 is The Motif 2 is NYBYTMYWTYBYHHVIAG, and the Motif 2 is The Motif 3 is DDKDKHH, and the Motif 3 is Wherein H is A or C or T, K is G or T, D is A or G or T, N is A or C or G or T, W is A or T, B is C or G or T, Y is C or T, M is A or C, and V is A or C or G; the circular RNA established by the circular RNA expression framework provided by the invention is higher in expression efficiency, can be accurately cyclized without generating a'scar sequence ', is low in immunogenicity, can realize the expression of circular RNA with various lengths, can construct a cell strain for stably expressing the target circular RNA, and provides a more advantageous tool for fundamental research and vaccine development of the circular RNA.

The technology relates in part to estimating fetal fraction in non-invasive prenatal testing using one or more fragmentomics parameters. In some aspects, the technology relates to estimating fetal fraction according to nucleic acid fragment lengths and sequence motif frequencies.

Described herein are olfactory receptor proteins having a modified C-terminal domain comprising a specific amino acid sequence motif, as well as related nucleic acid molecules, expression vectors, recombinant host cells, libraries, and methods and uses.

A method of analyzing a cfDNA from a biological sample to determine a level of a pathology in the biological sample of a subject comprises (i) determining an end sequence motif of at least one end of

A method for identifying adjacent sequence motifs, potency and specificity of nuclease is disclosed.

The present disclosure provides a structurally related family of pro-gelling decarboxylase homologues for use in commercial foods and cosmetics. The GPDH protein is expressed in cells in plants, animals and eukaryotic microorganisms in a trace form, and plays a catalytic role in a mevalonic acid pathway. Members of the GPDH family are structurally associated with one another through a series of strictly conserved amino acid sequence motifs. The ability to promote gelation when GPDH is used as a commercial product ingredient has been unclear yet before. The low gelation onset temperature (about 50 DEG C) and very low critical gelation concentration (4%) make the GPDH proteins of the present disclosure particularly suitable as functional protein substitutes in food and personal care products compared to most commonly used plant proteins and plant protein isolates.

The present invention relates to barcoded XTEN polypeptides and compositions thereof and methods of making and using the same, specifically disclosing polypeptides comprising an extended recombinant polypeptide (XTEN) comprising a plurality of overlapping sequence motifs and one or more barcode fragments that are releasable upon protease digestion and detectable from all other proteolytically releasable fragments. Certain embodiments of these polypeptides further comprise a biologically active polypeptide, with advantageous embodiments thereof comprising a proteolytic cleavage releasable segment capable of cleaving the linkage between the XTEN polypeptide and the biologically active polypeptide. Methods of making the polypeptides and methods of using the polypeptides are also disclosed.

Disclosed is a method for diagnosing cancer and predicting a cancer type using fragment end motif frequencies and sizes of cell-free nucleic acid, and more preferably, to a method for diagnosing cancer and predicting a cancer type by extracting nucleic acids from a biological sample to obtain sequence information, acquiring fragment end motif frequencies and sizes of nucleic acids based on the aligned reads, converting the fragment end motif frequencies and sizes of nucleic acids into vectorized data, inputting the vectorized data to a trained artificial intelligence model and analyzing a resulting calculated value. The method includes generating vectorized data and analyzing the same using an AI algorithm and thus is useful due to high sensitivity and accuracy thereof even in the case of low read coverage.

A method for measuring a fractional concentration of DNA from a first tissue type in a biological sample of a subject, the biological sample comprising cell-free DNA, the method comprises analysing a plurality of cell-free DNA molecules from the biological sample of the subject by (a) determining a genomic position in a reference genome corresponding to at least one end of the cell-free DNA molecule, (b) identifying a first set of CpG sites that all have a first differential methylation for the first tissue type in the reference genome, wherein the first set of CpG sites includes one or more CpG sites, (c) determining a first amount of cell-free DNA molecules ending at one of 0 or -1 position of any one of the first set of CpG sites or alternatively, (c) determining an end sequence motif of at least one end of the cell-free DNA molecule, wherein an end of the cell-free DNA molecule has a first position at an outermost position, a second position that is next to the first position, and a third position that is next to the second position; and (d) determining the fractional concentration of DNA from the first tissue type in the biological sample by comparing the first amount to a calibration value, wherein the calibration value is determined from one or more calibration samples having known fractional concentrations of DNA from the first tissue type.

The invention belongs to the technical field of deep learning, and particularly relates to an interpretable DNA sequence motif extraction and visualization method based on deep learning, and a motif extraction method based on combination of baseline input constructed based on a data set AGCT background and DeepLIFT attribution. A target motif length is parameterized into a normalized cut-off frequency, and a length controllable positioning frequency domain noise suppression scheme is realized through adjustable low-pass filtering; a screened motif set is obtained according to a dual screening standard formed by Fisher single-side inspection, BH-FDR correction and an effect quantity threshold value in a combined mode; an integrated link from site-by-site attribution to frequency domain noise suppression and length adjustability to statistics double-threshold robust screening to database comparison verification is established while the capability of capturing long-short motifs with different scales is ensured; the motif extraction not only can reflect the internal discrimination basis of the model, but also can maintain repeatable, comparable and traceable biological reliability in different data fields and application scenes.

Provided are some techniques that can use size and / or end motifs of cell-free DNA fragments to determine a concentration of cell-free DNA (all or clinically- relevant) in a biological sample of a subject, e.g., as a mass per volume. For example, a measured amount of cell-free DNA fragments at a particular size can be used with one or more calibration amounts determined from one or more calibration samples to determine a concentration of cell-free DNA. As another example, the measured amount can be of cell-free DNA fragments having a set of one or more sequence motifs corresponding to ending sequences of the plurality of cell-free DNA fragments. Certain sequence motif (s) can be selected.

The invention discloses an information processing method, device and equipment for pulmonary nodule malignant risk assessment, and relates to the technical field of pulmonary nodule malignant risk assessment. According to the method, the intricate relation among various characteristics of cfDNA is considered, four key characteristics and four comprehensive characteristics are extracted, and the length, the tail end motif, the sequence motif, the methylation rate and the relevance among the four characteristics of the cfDNA are covered. The features are coded and converted to obtain eight images, and the features are fused through a convolution fusion strategy. The pulmonary nodule malignant risk assessment method based on the cfDNA can break through the limitation of a traditional method, and can effectively learn the complex mode of the cfDNA on the pulmonary nodule malignant risk assessment, thereby realizing the accurate identification of the pulmonary nodule property, and improving the accuracy of predicting the malignant risk by means of the deep learning identification capability. The method provided by the invention is of great significance to comprehensive and accurate analysis of cfDNA characteristics.

The present invention relates to a Spinacia oleracea plant comprising a nucleic acid molecule which when homozygously present provides at least intermediate resistance to Peronospora effusa races Pe: 1, Pe: 2, Pe: 3, Pe: 4, Pe: 5, Pe: 6, Pe: 7, Pe: 8, Pe: 9, Pe: 10, Pe: 11, Pe: 12, Pe: 13, Pe: 14, Pe: 15, Pe: 16, Pe: 17, Pe: 18, Pe: 19 and Pe: 20, wherein said nucleic acid molecule comprises a gene which comprises a coding sequence according to SEQ ID NO: 1 and a gene which comprises a coding sequence according to SEQ ID NO: 2, or a gene which comprises a coding sequence having at least 95.0% sequence identity to SEQ ID NO: 7 and comprises an insertion of sequence motif GAAATA between nucleotides 1235 and 1236 of SEQ ID NO: 7 and a gene which comprises a coding sequence having at least 95.0% sequence identity to SEQ ID NO: 8 and lacks a sequence according to SEQ ID NO: 14, wherein the 95.0% sequence identity is over the part of SEQ ID NO: 8 without the lacking sequence, or genes comprising the corresponding genomic sequences or genes encoding a protein having an amino acid sequence according to SEQ ID NO: 3, and a gene encoding a protein having an amino acid sequence according to SEQ ID NO: 4, or genes encoding proteins showing 95% sequence identity thereto. The invention further relates to a plant carrying the nucleic acid molecule and to methods of selecting, producing and growing such plants.

The present disclosure is based on the identification of a novel sequence motif present in halogenase type enzymes. From this, the disclosure provides methods for identifying and or detecting halogenases (halogenating enzymes) and novel halogenases identifiable using such methods. The disclosure also provides a novel cohort of enzymes and novel methods for achieving substrate halogenation.